This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Colombel, M. Articles by Buttyan, R. Search for Related Content PubMed PubMed Citation Articles by Colombel, M. Articles by Buttyan, R.

American Journal of Pathology, Vol 143, 390-400, Copyright © 1993 by American Society for Investigative Pathology

REGULAR ARTICLES

Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone- refractory human prostate cancers

M Colombel, F Symmans, S Gil, KM O'Toole, D Chopin, M Benson, CA Olsson, S Korsmeyer and R Buttyan
Department of Urology, Columbia University College of Physicians and Surgeons, New York, New York 10032.

The oncoprotein encoded by bc1-2 is unique because of its intracellular location (a mitochondrial membrane protein) and apparent mode of action (suppression of apoptosis). To date, this oncogene has been associated only with the development of certain forms of human B-cell lymphoma. In this report, we describe our experience with a monoclonal antibody made against a synthetic peptide for bc1-2 that can recognize the bc1-2 protein and identify cells in human prostate glands expressing this proto-oncogene with in situ immunohistochemical procedures. These procedures were utilized to survey a series of 62 human tissues to evaluate whether bc1-2 might have a role in the developing prostate gland or in prostate oncogenesis. While all primordial epithelial cells in a fetal prostate gland immunostain for bc1-2, normal and hypertrophic prostate glands of the adult show bc1-2 expression restricted to the basal cells. All epithelial cells in areas of prostatic intraepithelial neoplasia were stained by this antibody, as were most (62%) localized invasive prostatic carcinomas. In contrast, all primary prostatic carcinomas and metastases obtained from metastatic prostate cancer patients after hormone treatment (hormone- refractory tumors) stained positive for bc1-2. This study demonstrates that the oncoprotein encoded by bc1-2 can be detected at sequential stages in the natural history of human prostate cancer. Since the bc1-2 oncoprotein is known to suppress the cellular response to apoptotic stimuli, it will be important to determine whether bc1-2 expression is a factor in the development of prostate cancers and in the survival of hormone-refractory prostate cancer cells.

This article has been cited by other articles:

				G. Liu, J. Kolesar, D. G. McNeel, C. Leith, K. Schell, J. Eickhoff, F. Lee, A. Traynor, R. Marnocha, D. Alberti, et al. A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors Clin. Cancer Res., May 1, 2008; 14(9): 2732 - 2739. [Abstract] [Full Text] [PDF]

				J. C. Reed Bcl-2-family proteins and hematologic malignancies: history and future prospects Blood, April 1, 2008; 111(7): 3322 - 3330. [Abstract] [Full Text] [PDF]

				T M Murphy, A S Perry, and M Lawler The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer Endocr. Relat. Cancer, March 1, 2008; 15(1): 11 - 25. [Abstract] [Full Text] [PDF]

				L. Y. Khor, J. Moughan, T. Al-Saleem, E. H. Hammond, V. Venkatesan, S. A. Rosenthal, M. A. Ritter, H. M. Sandler, G. E. Hanks, W. U. Shipley, et al. Bcl-2 and Bax Expression Predict Prostate Cancer Outcome in Men Treated with Androgen Deprivation and Radiotherapy on Radiation Therapy Oncology Group Protocol 92-02 Clin. Cancer Res., June 15, 2007; 13(12): 3585 - 3590. [Abstract] [Full Text] [PDF]

				D. Sarkar, I. V. Lebedeva, Z.-z. Su, E.-S. Park, L. Chatman, N. Vozhilla, P. Dent, D. T. Curiel, and P. B. Fisher Eradication of Therapy-Resistant Human Prostate Tumors Using a Cancer Terminator Virus Cancer Res., June 1, 2007; 67(11): 5434 - 5442. [Abstract] [Full Text] [PDF]

				T. Yoshino, H. Shiina, S. Urakami, N. Kikuno, T. Yoneda, K. Shigeno, and M. Igawa Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin. Cancer Res., October 15, 2006; 12(20): 6116 - 6124. [Abstract] [Full Text] [PDF]

				C. Castilla, B. Congregado, D. Chinchon, F. J. Torrubia, M. A. Japon, and C. Saez Bcl-xL Is Overexpressed in Hormone-Resistant Prostate Cancer and Promotes Survival of LNCaP Cells via Interaction with Proapoptotic Bak Endocrinology, October 1, 2006; 147(10): 4960 - 4967. [Abstract] [Full Text] [PDF]

				S.-J. Kim, H. Uehara, S. Yazici, J. E. Busby, T. Nakamura, J. He, M. Maya, C. Logothetis, P. Mathew, X. Wang, et al. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst, June 7, 2006; 98(11): 783 - 793. [Abstract] [Full Text] [PDF]

				K. J. Pienta and D. Bradley Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res., March 15, 2006; 12(6): 1665 - 1671. [Full Text] [PDF]

				Y. Tang, M. A. Khan, O. Goloubeva, D. I. Lee, D. Jelovac, A. M. Brodie, and A. Hussain Docetaxel Followed by Castration Improves Outcomes in LNCaP Prostate Cancer-Bearing Severe Combined Immunodeficient Mice Clin. Cancer Res., January 1, 2006; 12(1): 169 - 174. [Abstract] [Full Text] [PDF]

				M. GLEAVE and K. N. CHI Knock-down of the Cytoprotective Gene, Clusterin, to Enhance Hormone and Chemosensitivity in Prostate and Other Cancers Ann. N.Y. Acad. Sci., November 1, 2005; 1058(1): 1 - 15. [Abstract] [Full Text] [PDF]

				K. Yamanaka, P. Rocchi, H. Miyake, L. Fazli, B. Vessella, U. Zangemeister-Wittke, and M. E. Gleave A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells Mol. Cancer Ther., November 1, 2005; 4(11): 1689 - 1698. [Abstract] [Full Text] [PDF]

				A. W. Tolcher, K. Chi, J. Kuhn, M. Gleave, A. Patnaik, C. Takimoto, G. Schwartz, I. Thompson, K. Berg, S. D'Aloisio, et al. A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3854 - 3861. [Abstract] [Full Text] [PDF]

				A. Hussain, N. Dawson, P. Amin, C. Engstrom, B. Dorsey, E. Siegel, and C. Guo Docetaxel Followed by Hormone Therapy in Men Experiencing Increasing Prostate-Specific Antigen After Primary Local Treatments for Prostate Cancer J. Clin. Oncol., April 20, 2005; 23(12): 2789 - 2796. [Abstract] [Full Text] [PDF]

				W. E. Grizzle, D. G. Bostwick, H. Burke, O. W. Tawfik, D. McGregor, J. Cohn, and R. Lieberman Biomarkers in Prostate Cancer Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 196 - 204. [Full Text] [PDF]

				J. Marshall, H. Chen, D. Yang, M. Figueira, K. B. Bouker, Y. Ling, M. Lippman, S. R. Frankel, and D. F. Hayes A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors Ann. Onc., August 1, 2004; 15(8): 1274 - 1283. [Abstract] [Full Text] [PDF]

				A. W. Tolcher, J. Kuhn, G. Schwartz, A. Patnaik, L. A. Hammond, I. Thompson, H. Fingert, D. Bushnell, S. Malik, J. Kreisberg, et al. A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer Clin. Cancer Res., August 1, 2004; 10(15): 5048 - 5057. [Abstract] [Full Text] [PDF]

				M. H. Rashid and U. B. Chaudhary Intermittent Androgen Deprivation Therapy for Prostate Cancer Oncologist, June 1, 2004; 9(3): 295 - 301. [Abstract] [Full Text] [PDF]

				C. A. Heinlein and C. Chang Androgen Receptor in Prostate Cancer Endocr. Rev., April 1, 2004; 25(2): 276 - 308. [Abstract] [Full Text] [PDF]

				M. GLEAVE and B. JANSEN Clusterin and IGFBPs as Antisense Targets in Prostate Cancer Ann. N.Y. Acad. Sci., December 1, 2003; 1002(1): 95 - 104. [Abstract] [Full Text] [PDF]

				M. Grzmil, P. Thelen, B. Hemmerlein, S. Schweyer, S. Voigt, D. Mury, and P. Burfeind Bax Inhibitor-1 Is Overexpressed in Prostate Cancer and Its Specific Down-Regulation by RNA Interference Leads to Cell Death in Human Prostate Carcinoma Cells Am. J. Pathol., August 1, 2003; 163(2): 543 - 552. [Abstract] [Full Text] [PDF]

				S. K. Cheema, S. K. Mishra, V. M. Rangnekar, A. M. Tari, R. Kumar, and G. Lopez-Berestein Par-4 Transcriptionally Regulates Bcl-2 through a WT1-binding Site on the bcl-2 Promoter J. Biol. Chem., May 23, 2003; 278(22): 19995 - 20005. [Abstract] [Full Text] [PDF]

				C. P. Tran, C. Lin, J. Yamashiro, and R. E. Reiter Prostate Stem Cell Antigen Is a Marker of Late Intermediate Prostate Epithelial Cells Mol. Cancer Res., December 1, 2002; 1(2): 113 - 121. [Abstract] [Full Text] [PDF]

				N. L. Tran, D. G. Adams, R. R. Vaillancourt, and R. L. Heimark Signal Transduction from N-cadherin Increases Bcl-2. REGULATION OF THE PHOSPHATIDYLINOSITOL 3-KINASE/Akt PATHWAY BY HOMOPHILIC ADHESION AND ACTIN CYTOSKELETAL ORGANIZATION J. Biol. Chem., August 30, 2002; 277(36): 32905 - 32914. [Abstract] [Full Text] [PDF]

				S. Goodin, K. V. Rao, and R. S. DiPaola State-of-the-Art Treatment of Metastatic Hormone-Refractory Prostate Cancer Oncologist, August 1, 2002; 7(4): 360 - 370. [Abstract] [Full Text] [PDF]

				Y. ZHANG, B. NAN, J. YU, T. SNABBOON, F. ANDRIANI, and M. MARCELLI From Castration-Induced Apoptosis of Prostatic Epithelium to the Use of Apoptotic Genes in the Treatment of Prostate Cancer Ann. N.Y. Acad. Sci., June 1, 2002; 963(1): 191 - 203. [Abstract] [Full Text] [PDF]

				M. J. Morris, W. P. Tong, C. Cordon-Cardo, M. Drobnjak, W. K. Kelly, S. F. Slovin, K. L. Terry, K. Siedlecki, P. Swanson, M. Rafi, et al. Phase I Trial of BCL-2 Antisense Oligonucleotide (G3139) Administered by Continuous Intravenous Infusion in Patients with Advanced Cancer Clin. Cancer Res., March 1, 2002; 8(3): 679 - 683. [Abstract] [Full Text] [PDF]

				Y.-G. Chen, H. M. Lui, S.-L. Lin, J. M. Lee, and S.-Y. Ying Regulation of Cell Proliferation, Apoptosis, and Carcinogenesis by Activin Experimental Biology and Medicine, February 1, 2002; 227(2): 75 - 87. [Abstract] [Full Text] [PDF]

				K. N. Chi, M. E. Gleave, R. Klasa, N. Murray, C. Bryce, D. E. Lopes de Menezes, S. D'Aloisio, and A. W. Tolcher A Phase I Dose-finding Study of Combined Treatment with an Antisense Bcl-2 Oligonucleotide (Genasense) and Mitoxantrone in Patients with Metastatic Hormone-refractory Prostate Cancer Clin. Cancer Res., December 1, 2001; 7(12): 3920 - 3927. [Abstract] [Full Text] [PDF]

				M. E. Grossmann, H. Huang, and D. J. Tindall Androgen Receptor Signaling in Androgen-Refractory Prostate Cancer J Natl Cancer Inst, November 21, 2001; 93(22): 1687 - 1697. [Abstract] [Full Text] [PDF]

				H. Huang, J. C. Cheville, Y. Pan, P. C. Roche, L. J. Schmidt, and D. J. Tindall PTEN Induces Chemosensitivity in PTEN-mutated Prostate Cancer Cells by Suppression of Bcl-2 Expression J. Biol. Chem., October 12, 2001; 276(42): 38830 - 38836. [Abstract] [Full Text] [PDF]

				T. Zellweger, H. Miyake, S. Cooper, K. Chi, B. S. Conklin, B. P. Monia, and M. E. Gleave Antitumor Activity of Antisense Clusterin Oligonucleotides Is Improved in Vitro and in Vivo by Incorporation of 2'-O-(2-Methoxy)Ethyl Chemistry J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 934 - 940. [Abstract] [Full Text]

				S. Signoretti and M. Loda Estrogen Receptor {beta} in Prostate Cancer : Brake Pedal or Accelerator? Am. J. Pathol., July 1, 2001; 159(1): 13 - 16. [Full Text] [PDF]

				E. M. Bruckheimer and N. Kyprianou Dihydrotestosterone Enhances Transforming Growth Factor-{beta}-Induced Apoptosis in Hormone-Sensitive Prostate Cancer Cells Endocrinology, June 1, 2001; 142(6): 2419 - 2426. [Abstract] [Full Text] [PDF]

				Y. Chen, J. Wang, M. M. Fraig, J. Metcalf, W. R. Turner, N. K. Bissada, D. K. Watson, and C. W. Schweinfest Defects of DNA Mismatch Repair in Human Prostate Cancer Cancer Res., May 1, 2001; 61(10): 4112 - 4121. [Abstract] [Full Text]

				S. F. Shariat, S. Desai, W. Song, T. Khan, J. Zhao, C. Nguyen, B. A. Foster, N. Greenberg, D. M. Spencer, and K. M. Slawin Adenovirus-mediated Transfer of Inducible Caspases: A Novel "Death Switch" Gene Therapeutic Approach to Prostate Cancer Cancer Res., March 1, 2001; 61(6): 2562 - 2571. [Abstract] [Full Text]

				X. Li, M. Marani, R. Mannucci, B. Kinsey, F. Andriani, I. Nicoletti, L. Denner, and M. Marcelli Overexpression of BCL-XL Underlies the Molecular Basis for Resistance to Staurosporine-induced Apoptosis in PC-3 Cells Cancer Res., February 1, 2001; 61(4): 1699 - 1706. [Abstract] [Full Text]

				S. Signoretti, D. Waltregny, J. Dilks, B. Isaac, D. Lin, L. Garraway, A. Yang, R. Montironi, F. McKeon, and M. Loda p63 Is a Prostate Basal Cell Marker and Is Required for Prostate Development Am. J. Pathol., December 1, 2000; 157(6): 1769 - 1775. [Abstract] [Full Text] [PDF]

				C. Abate-Shen and M. M. Shen Molecular genetics of prostate cancer Genes & Dev., October 1, 2000; 14(19): 2410 - 2434. [Full Text]

				J. K. Jackson, M. E. Gleave, V. Yago, E. Beraldi, W. L. Hunter, and H. M. Burt The Suppression of Human Prostate Tumor Growth in Mice by the Intratumoral Injection of a Slow-Release Polymeric Paste Formulation of Paclitaxel Cancer Res., August 1, 2000; 60(15): 4146 - 4151. [Abstract] [Full Text]

				M. S. Steiner, X. Zhang, Y. Wang, and Y. Lu Growth Inhibition of Prostate Cancer by an Adenovirus Expressing a Novel Tumor Suppressor Gene, pHyde Cancer Res., August 1, 2000; 60(16): 4419 - 4425. [Abstract] [Full Text]

				C. Crescioli, M. Maggi, G. B. Vannelli, M. Luconi, R. Salerno, T. Barni, M. Gulisano, G. Forti, and M. Serio Effect of a Vitamin D3 Analogue on Keratinocyte Growth Factor-Induced Cell Proliferation in Benign Prostate Hyperplasia J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2576 - 2583. [Abstract] [Full Text]

				H. Perlman, C. Georganas, L. J. Pagliari, A. E. Koch, K. Haines III, and R. M. Pope Bcl-2 Expression in Synovial Fibroblasts Is Essential for Maintaining Mitochondrial Homeostasis and Cell Viability J. Immunol., May 15, 2000; 164(10): 5227 - 5235. [Abstract] [Full Text] [PDF]

				A.-L. Hsu, T.-T. Ching, D.-S. Wang, X. Song, V. M. Rangnekar, and C.-S. Chen The Cyclooxygenase-2 Inhibitor Celecoxib Induces Apoptosis by Blocking Akt Activation in Human Prostate Cancer Cells Independently of Bcl-2 J. Biol. Chem., April 6, 2000; 275(15): 11397 - 11403. [Abstract] [Full Text] [PDF]

				T. Nakashima, M. Miura, and M. Hara Tetrocarcin A Inhibits Mitochondrial Functions of Bcl-2 and Suppresses Its Anti-apoptotic Activity Cancer Res., March 1, 2000; 60(5): 1229 - 1235. [Abstract] [Full Text]

				Z Kolár, P G Murray, K Scott, A Harrison, B Vojtesek, and J Dusek Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer Mol. Pathol., February 1, 2000; 53(1): 15 - 18. [Abstract] [Full Text]

				H. Miayake, A. Tolcher, and M. E. Gleave Chemosensitization and Delayed Androgen-Independent Recurrence of Prostate Cancer With the Use of Antisense Bcl-2 Oligodeoxynucleotides J Natl Cancer Inst, January 5, 2000; 92(1): 34 - 41. [Abstract] [Full Text] [PDF]

				S. E. Blutt, T. J. McDonnell, T. C. Polek, and N. L. Weigel Calcitriol-Induced Apoptosis in LNCaP Cells Is Blocked By Overexpression of Bcl-2 Endocrinology, January 1, 2000; 141(1): 10 - 17. [Abstract] [Full Text] [PDF]

				L. Cheng, T. M. Pisansky, T. J. Sebo, B. C. Leibovich, D. M. Ramnani, A. L. Weaver, B. G. Scherer, M. L. Blute, H. Zincke, and D. G. Bostwick Cell Proliferation in Prostate Cancer Patients with Lymph Node Metastasis: A Marker for Progression Clin. Cancer Res., October 1, 1999; 5(10): 2820 - 2823. [Abstract] [Full Text] [PDF]

				J. C. Reed Dysregulation of Apoptosis in Cancer J. Clin. Oncol., September 1, 1999; 17(9): 2941 - 2941. [Abstract] [Full Text] [PDF]

				H. Miyake, A. Tolcher, and M. E. Gleave Antisense Bcl-2 Oligodeoxynucleotides Inhibit Progression to Androgen-Independence after Castration in the Shionogi Tumor Model Cancer Res., August 1, 1999; 59(16): 4030 - 4034. [Abstract] [Full Text] [PDF]

				P. J Medina, R. S DiPaola, and S. Goodin Treatment of hormone-refractory prostate cancer Journal of Oncology Pharmacy Practice, March 1, 1999; 5(1): 32 - 48. [Abstract] [PDF]

				M. P. Waalkes and B. A. Diwan Cadmium-induced inhibition of the growth and metastasis of human lung carcinoma xenografts: role of apoptosis Carcinogenesis, January 1, 1999; 20(1): 65 - 70. [Abstract] [Full Text] [PDF]

				M. Marcelli, G. R. Cunningham, M. Walkup, Z. He, L. Sturgis, C. Kagan, R. Mannucci, I. Nicoletti, B. Teng, and L. Denner Signaling Pathway Activated during Apoptosis of the Prostate Cancer Cell Line LNCaP: Overexpression of Caspase-7 as a New Gene Therapy Strategy for Prostate Cancer Cancer Res., January 1, 1999; 59(2): 382 - 390. [Abstract] [Full Text] [PDF]

				Y. Soini, P. Paakko, and V-P. Lehto Histopathological Evaluation of Apoptosis in Cancer Am. J. Pathol., October 1, 1998; 153(4): 1041 - 1053. [Full Text] [PDF]

				M Ilyas, X-P Hao, K Wilkinson, I P M Tomlinson, A M Abbasi, A Forbes, W F Bodmer, and I C Talbot Loss of Bcl-2 expression correlates with tumour recurrence in colorectal cancer Gut, September 1, 1998; 43(3): 383 - 387. [Abstract] [Full Text] [PDF]

				N. N. Nupponen, L. Kakkola, P. Koivisto, and T. Visakorpi Genetic Alterations in Hormone-Refractory Recurrent Prostate Carcinomas Am. J. Pathol., July 1, 1998; 153(1): 141 - 148. [Abstract] [Full Text] [PDF]

				R. E. Reiter, Z. Gu, T. Watabe, G. Thomas, K. Szigeti, E. Davis, M. Wahl, S. Nisitani, J. Yamashiro, M. M. Le Beau, et al. Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer PNAS, February 17, 1998; 95(4): 1735 - 1740. [Abstract] [Full Text] [PDF]